These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22030800)

  • 1. The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension.
    Fernandes CJCS; Dias BA; Jardim CVP; Hovnanian A; Hoette S; Morinaga LK; Souza S; Suesada M; Breda AP; Souza R
    Chest; 2012 Apr; 141(4):923-928. PubMed ID: 22030800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival in schistosomiasis-associated pulmonary arterial hypertension.
    dos Santos Fernandes CJ; Jardim CV; Hovnanian A; Hoette S; Dias BA; Souza S; Humbert M; Souza R
    J Am Coll Cardiol; 2010 Aug; 56(9):715-20. PubMed ID: 20723801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension.
    Hoette S; Figueiredo C; Dias B; Alves JL; Gavilanes F; Prada LF; Jasinowodolinski D; Morinaga LT; Jardim C; Fernandes CJ; Souza R
    BMC Pulm Med; 2015 Oct; 15():118. PubMed ID: 26459359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
    Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
    Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases.
    Alves JL; Gavilanes F; Jardim C; Fernandes CJCDS; Morinaga LTK; Dias B; Hoette S; Humbert M; Souza R
    Chest; 2015 Feb; 147(2):495-501. PubMed ID: 25317567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
    Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
    Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting cardiopulmonary responses to incremental exercise in patients with schistosomiasis-associated and idiopathic pulmonary arterial hypertension with similar resting hemodynamic impairment.
    Valois FM; Nery LE; Ramos RP; Ferreira EV; Silva CC; Neder JA; Ota-Arakaki JS
    PLoS One; 2014; 9(2):e87699. PubMed ID: 24498356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study.
    Hay BR; Pugh ME; Robbins IM; Hemnes AR
    Chest; 2016 Mar; 149(3):660-6. PubMed ID: 26378379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors.
    Sakao S; Tanabe N; Kasahara Y; Tatsumi K
    Intern Med; 2012; 51(19):2721-6. PubMed ID: 23037462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schistosomiasis-associated pulmonary arterial hypertension: a systematic review.
    Knafl D; Gerges C; King CH; Humbert M; Bustinduy AL
    Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32024722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies.
    Mendes AA; Roncal CGP; Oliveira FRA; Albuquerque ES; Góes GHB; Piscoya ICV; Sobral Filho DC
    Rev Soc Bras Med Trop; 2020; 53():e20190418. PubMed ID: 32049203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other causes of PAH (schistosomiasis, porto-pulmonary hypertension and hemolysis-associated pulmonary hypertension).
    Souza R; Fernandes CJ; Jardim CV
    Semin Respir Crit Care Med; 2009 Aug; 30(4):448-57. PubMed ID: 19634084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy in pulmonary arterial hypertension.
    Pugh ME; Hemnes AR; Robbins IM
    Clin Chest Med; 2013 Dec; 34(4):841-55. PubMed ID: 24267308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
    Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension.
    Woods PR; Taylor BJ; Frantz RP; Johnson BD
    Am J Cardiol; 2012 Apr; 109(7):1066-72. PubMed ID: 22245407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.